Evidence map›Paper›PMID 39995104›Full record

ArticleCurrent protocols2025

Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy.

Deepti Bhatt, Ranjini K Sundaram, Karla S Lugo López, Teresa Lee, Susan E Gueble, Juan C Vasquez

Abstract read
In one paragraph

Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Deepti BhattDepartment of Pediatrics, Yale School of Medicine, New Haven, Connecticut.
Ranjini K SundaramDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Karla S Lugo LópezUniversity of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Teresa LeeDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Susan E GuebleDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Juan C VasquezDepartment of Pediatrics, Yale School of Medicine, New Haven, Connecticut.ORCID https://orcid.org/0000-0002-9031-7639

Funding

Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomasK08CA258796 · NCI · YALE UNIVERSITY · PI VASQUEZ, JUAN C · 2021 to 2025
$1.2M
NCI NIH HHS K08 CA258796
6 · The paper itself

Abstract

Glioblastoma (GBM) carries a dismal prognosis, with a median survival of less than 15 months. Temozolomide (TMZ), the standard frontline chemotherapeutic for GBM, is an alkylating agent that generates DNA O

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsDisease Models, AnimalDNA Mismatch RepairGliomaImmunotherapyAnimalsCell Line, TumorCRISPR-Cas SystemsMiceMutL Protein Homolog 1TemozolomideAntineoplastic Agents, AlkylatingMlh1 protein, mouseMutL Protein Homolog 1Temozolomidegliomamismatch repairsyngeneic mouse modeltemozolomide

Identifiers

PMID39995104
PMCPMC12183790

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.